Review Article| Volume 37, ISSUE 4, P787-802, December 2017

How Do We Use Multicolor Flow Cytometry to Detect Minimal Residual Disease in Acute Myeloid Leukemia?

Published:September 26, 2017DOI:


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribers receive full online access to your subscription and archive of back issues up to and including 2002.

      Content published before 2002 is available via pay-per-view purchase only.


      Subscribe to Clinics in Laboratory Medicine
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Ravandi F.
        Relapsed acute myeloid leukemia: why is there no standard of care?.
        Best Pract Res Clin Haematol. 2013; 26: 253-259
        • Bachas C.
        • Schuurhuis G.J.
        • Assaraf Y.G.
        • et al.
        The role of minor subpopulations within the leukemic blast compartment of AML patients at initial diagnosis in the development of relapse.
        Leukemia. 2012; 26: 1313-1320
        • Inaba H.
        • Coustan-Smith E.
        • Cao X.
        • et al.
        Comparative analysis of different approaches to measure treatment response in acute myeloid leukemia.
        J Clin Oncol. 2012; 30: 3625-3632
        • Loken M.R.
        • Alonzo T.A.
        • Pardo L.
        • et al.
        Residual disease detected by multidimensional flow cytometry signifies high relapse risk in patients with de novo acute myeloid leukemia: a report from Children's Oncology Group.
        Blood. 2012; 120: 1581-1588
        • Ouyang J.
        • Goswami M.
        • Peng J.
        • et al.
        Comparison of multiparameter flow cytometry immunophenotypic analysis and quantitative RT-PCR for the detection of minimal residual disease of core binding factor acute myeloid leukemia.
        Am J Clin Pathol. 2016; 145: 769-777
        • Buccisano F.
        • Maurillo L.
        • Del Principe M.I.
        • et al.
        Prognostic and therapeutic implications of minimal residual disease detection in acute myeloid leukemia.
        Blood. 2012; 119: 332-341
        • Venditti A.
        • Buccisano F.
        • Del Poeta G.
        • et al.
        Level of minimal residual disease after consolidation therapy predicts outcome in acute myeloid leukemia.
        Blood. 2000; 96: 3948-3952
        • Kern W.
        • Voskova D.
        • Schoch C.
        • et al.
        Determination of relapse risk based on assessment of minimal residual disease during complete remission by multiparameter flow cytometry in unselected patients with acute myeloid leukemia.
        Blood. 2004; 104: 3078-3085
        • Sievers E.L.
        • Lange B.J.
        • Alonzo T.A.
        • et al.
        Immunophenotypic evidence of leukemia after induction therapy predicts relapse: results from a prospective Children's Cancer Group study of 252 patients with acute myeloid leukemia.
        Blood. 2003; 101: 3398-3406
        • San Miguel J.F.
        • Martinez A.
        • Macedo A.
        • et al.
        Immunophenotyping investigation of minimal residual disease is a useful approach for predicting relapse in acute myeloid leukemia patients.
        Blood. 1997; 90: 2465-2470
        • Feller N.
        • van der Pol M.A.
        • van Stijn A.
        • et al.
        MRD parameters using immunophenotypic detection methods are highly reliable in predicting survival in acute myeloid leukaemia.
        Leukemia. 2004; 18: 1380-1390
        • San Miguel J.F.
        • Vidriales M.B.
        • Lopez-Berges C.
        • et al.
        Early immunophenotypical evaluation of minimal residual disease in acute myeloid leukemia identifies different patient risk groups and may contribute to postinduction treatment stratification.
        Blood. 2001; 98: 1746-1751
        • Buccisano F.
        • Maurillo L.
        • Gattei V.
        • et al.
        The kinetics of reduction of minimal residual disease impacts on duration of response and survival of patients with acute myeloid leukemia.
        Leukemia. 2006; 20: 1783-1789
        • Freeman S.D.
        • Virgo P.
        • Couzens S.
        • et al.
        Prognostic relevance of treatment response measured by flow cytometric residual disease detection in older patients with acute myeloid leukemia.
        J Clin Oncol. 2013; 31: 4123-4131
        • Ravandi F.
        • Jorgensen J.
        • Borthakur G.
        • et al.
        Persistence of minimal residual disease assessed by multiparameter flow cytometry is highly prognostic in younger patients with acute myeloid leukemia.
        Cancer. 2017; 123: 426-435
        • Walter R.B.
        • Buckley S.A.
        • Pagel J.M.
        • et al.
        Significance of minimal residual disease before myeloablative allogeneic hematopoietic cell transplantation for AML in first and second complete remission.
        Blood. 2013; 122: 1813-1821
        • Walter R.B.
        • Gooley T.A.
        • Wood B.L.
        • et al.
        Impact of pretransplantation minimal residual disease, as detected by multiparametric flow cytometry, on outcome of myeloablative hematopoietic cell transplantation for acute myeloid leukemia.
        J Clin Oncol. 2011; 29: 1190-1197
        • Appelbaum F.R.
        Measurement of minimal residual disease before and after myeloablative hematopoietic cell transplantation for acute leukemia.
        Best Pract Res Clin Haematol. 2013; 26: 279-284
        • Oran B.
        • Jorgensen J.L.
        • Marin D.
        • et al.
        Pre-transplantation minimal residual disease with cytogenetic and molecular diagnostic features improves risk stratification in acute myeloid leukemia.
        Haematologica. 2017; 102: 110-117
        • Kern W.
        • Haferlach C.
        • Haferlach T.
        • et al.
        Monitoring of minimal residual disease in acute myeloid leukemia.
        Cancer. 2008; 112: 4-16
        • Kern W.
        • Bacher U.
        • Haferlach C.
        • et al.
        The role of multiparameter flow cytometry for disease monitoring in AML.
        Best Pract Res Clin Haematol. 2010; 23: 379-390
        • Baer M.R.
        • Stewart C.C.
        • Dodge R.K.
        • et al.
        High frequency of immunophenotype changes in acute myeloid leukemia at relapse: implications for residual disease detection (Cancer and Leukemia Group B Study 8361).
        Blood. 2001; 97: 3574-3580
        • Voskova D.
        • Schoch C.
        • Schnittger S.
        • et al.
        Stability of leukemia-associated aberrant immunophenotypes in patients with acute myeloid leukemia between diagnosis and relapse: comparison with cytomorphologic, cytogenetic, and molecular genetic findings.
        Cytometry B Clin Cytom. 2004; 62: 25-38
        • Zeijlemaker W.
        • Gratama J.W.
        • Schuurhuis G.J.
        Tumor heterogeneity makes AML a “moving target” for detection of residual disease.
        Cytometry B Clin Cytom. 2014; 86: 3-14
        • Huang L.
        • Garcia-Manero G.
        • Jabbour E.
        • et al.
        Persistence of immunophenotypically aberrant CD34+ myeloid progenitors is frequent in bone marrow of patients with myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms treated with hypomethylating agents.
        J Clin Pathol. 2016; 69: 1001-1008
        • Quintas-Cardama A.
        • Ravandi F.
        • Liu-Dumlao T.
        • et al.
        Epigenetic therapy is associated with similar survival compared with intensive chemotherapy in older patients with newly diagnosed acute myeloid leukemia.
        Blood. 2012; 120: 4840-4845
        • van Rhenen A.
        • Moshaver B.
        • Kelder A.
        • et al.
        Aberrant marker expression patterns on the CD34+CD38- stem cell compartment in acute myeloid leukemia allows to distinguish the malignant from the normal stem cell compartment both at diagnosis and in remission.
        Leukemia. 2007; 21: 1700-1707
        • Ding L.
        • Ley T.J.
        • Larson D.E.
        • et al.
        Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing.
        Nature. 2012; 481: 506-510
        • Pollyea D.A.
        • Kohrt H.E.
        • Medeiros B.C.
        Acute myeloid leukaemia in the elderly: a review.
        Br J Haematol. 2011; 152: 524-542
        • Heinemann V.
        • Jehn U.
        Acute myeloid leukemia in the elderly: biological features and search for adequate treatment.
        Ann Hematol. 1991; 63: 179-188
        • Medeiros B.C.
        • Othus M.
        • Fang M.
        • et al.
        Prognostic impact of monosomal karyotype in young adult and elderly acute myeloid leukemia: the Southwest Oncology Group (SWOG) experience.
        Blood. 2010; 116: 2224-2228
        • Wilson C.S.
        • Davidson G.S.
        • Martin S.B.
        • et al.
        Gene expression profiling of adult acute myeloid leukemia identifies novel biologic clusters for risk classification and outcome prediction.
        Blood. 2006; 108: 685-696
        • de Jonge H.J.
        • de Bont E.S.
        • Valk P.J.
        • et al.
        AML at older age: age-related gene expression profiles reveal a paradoxical down-regulation of p16INK4A mRNA with prognostic significance.
        Blood. 2009; 114: 2869-2877
        • Rao A.V.
        • Valk P.J.
        • Metzeler K.H.
        • et al.
        Age-specific differences in oncogenic pathway dysregulation and anthracycline sensitivity in patients with acute myeloid leukemia.
        J Clin Oncol. 2009; 27: 5580-5586
        • Majeti R.
        Clonal evolution of pre-leukemic hematopoietic stem cells precedes human acute myeloid leukemia.
        Best Pract Res Clin Haematol. 2014; 27: 229-234
        • Majeti R.
        • Weissman I.L.
        Human acute myelogenous leukemia stem cells revisited: there's more than meets the eye.
        Cancer Cell. 2011; 19: 9-10
        • Al-Ali H.K.
        • Jaekel N.
        • Niederwieser D.
        The role of hypomethylating agents in the treatment of elderly patients with AML.
        J Geriatr Oncol. 2014; 5: 89-105